Evidence map›Paper›PMID 25063244›Full record

ArticleThe European respiratory journal2014

Smoking-related idiopathic interstitial pneumonia.

Kevin R Flaherty, Charlene Fell, Marie-Christine Aubry, Kevin Brown, Thomas Colby, Ulrich Costabel, Teri J Franks, Barry H Gross, David M Hansell, Ella Kazerooni and 15 more

Open access · bronzeAbstract read
In one paragraph

Article in The European respiratory journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Sex and gender in interstitial lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2021
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Smoking and interstitial lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 14 institutions in 8 countries.

Kevin R FlahertyDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA Both authors contributed equally.
Charlene FellDivision of Respiratory Medicine, University of Calgary, Calgary, AB, Canada Both authors contributed equally.
Marie-Christine AubryDept of Pathology, Mayo Clinic, Rochester, MN, USA.
Kevin BrownDivision of Pulmonary Medicine, National Jewish Medical and Research Center, Denver, CO, USA.
Thomas ColbyDept of Pathology, Mayo Clinic, Scottsdale, AZ, USA.
Ulrich CostabelDept of Pneumology/Allergy, Ruhrlandklinik, University Hospital, Essen, Germany.
Teri J FranksDept of Pulmonary and Mediastinal Pathology, The Joint Pathology Center, Silver Spring, MD, USA.
Barry H GrossDept of Radiology, University of Michigan, Ann Arbor, MI, USA.
David M HansellDept of Radiology, Royal Brompton Hospital, London, UK.
Ella KazerooniDept of Radiology, University of Michigan, Ann Arbor, MI, USA.
Dong Soon KimDept of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea.
Talmadge E KingDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, CA, USA.
Masanori KitachiNational Hospital Organization Kinki-Chuo, Osaka, Japan.
David LynchDept of Radiology, National Jewish Medical and Research Center, Denver, CO, USA.
Jeff MyersDept of Pathology, University of Michigan, Ann Arbor, MI, USA.
Sonoko NagaiRespiratory Medicine, Kyoto University, Kyoto, Japan.
Andrew G NicholsonDept of Histopathology, Royal Brompton Hospital, London, UK.
Venerino PolettiDipartimento di Malattie del Torace, Universita di Parma, Forli, Italy.
Ganesh RaghuDivision of Pulmonary Medicine, University of Washington, Seattle, WA, USA.
Moises SelmanInstituto Nacional de Enfermedades Respiratorias, Mexico DF, Mexico.
Galen ToewsDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
William TravisDept of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Athol U WellsInterstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
Robert VassalloDivision of Pulmonary, Allergy and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Fernando J MartinezDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA Dept of Medicine, Division of Pulmonary and Critical Care Medicine, Weill Cornell Medical Center, New York, NY, USA fjm2003@med.cornell.edu.
University of Michigan–Ann Arbor · USRoyal Brompton Hospital · GBUniversity of Colorado Denver · USInstituto Nacional de Enfermedades Respiratorias · MXKyoto University · JPMemorial Sloan Kettering Cancer Center · USNational Kinki Chuo Hospital for Chest Disease · JPPulmonary Associates · USRuhrlandklinik · DEUniversity of Calgary · CAUniversity of California, San Francisco · USUniversity of Parma · ITUniversity of Ulsan · KRUniversity of Washington · US

Funding

Forging a road to personalized medicine in interstitial lung diseasesK24HL111316 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FLAHERTY, KEVIN R · 2012 to 2017
$909k
NHLBI NIH HHS K24 HL111316
6 · The paper itself

Abstract

Cigarette smoking is a key factor in the development of numerous pulmonary diseases. An international group of clinicians, radiologists and pathologists evaluated patients with previously identified idiopathic interstitial pneumonia (IIP) to determine unique features of cigarette smoking. Phase 1 (derivation group) identified smoking-related features in patients with a history of smoking (n=41). Phase 2 (validation group) determined if these features correctly predicted the smoking status of IIP patients (n=100) to participants blinded to smoking history. Finally, the investigators sought to determine if a new smoking-related interstitial lung disease phenotype could be defined. Phase 1 suggested that preserved forced vital capacity with disproportionately reduced diffusing capacity of the lung for carbon monoxide, and various radiographic and histopathological findings were smoking-related features. In phase 2, the kappa coefficient among clinicians was 0.16 (95% CI 0.11-0.21), among the pathologists 0.36 (95% CI 0.32-0.40) and among the radiologists 0.43 (95% CI 0.35-0.52) for smoking-related features. Eight of the 100 cases were felt to represent a potential smoking-related interstitial lung disease. Smoking-related features of interstitial lung disease were identified in a minority of smokers and were not specific for smoking. This study is limited by its retrospective design, the potential for recall bias in smoking history and lack of information on second-hand smoke exposure. Further research is needed to understand the relationship between smoking and interstitial lung disease.

Indexed as

AdultAgedCarbon MonoxideFemaleHumansIdiopathic Interstitial PneumoniasInternational CooperationMaleMental RecallMexicoMiddle AgedModels, OrganizationalPrognosisPulmonary MedicineRadiologyRepublic of KoreaCarbon MonoxideTobacco Smoke Pollution

Identifiers

PMID25063244
PMCPMC4366053
OpenAlexW2017347713

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.